NYSE:CBM - Cambrex Stock Price, News, & Analysis

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to the consensus estimate of $122.04 million. Cambrex had a return on equity of 22.20% and a net margin of 22.67%. The company's quarterly revenue was down 7.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.55 EPS. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Cambrex.

Cambrex updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.79.

5 equities research analysts have issued 1 year price objectives for Cambrex's stock. Their predictions range from $63.00 to $75.50. On average, they expect Cambrex's share price to reach $69.25 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Media headlines about CBM stock have been trending somewhat negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cambrex earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days.

Some companies that are related to Cambrex include Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR), Catalent (CTLT), TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS) and Evotec (EVTCY).

Cambrex's stock is owned by a number of of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (1.17%), Summit Creek Advisors LLC (0.68%), Confluence Investment Management LLC (0.28%), Scout Investments Inc. (0.27%), IMA Wealth Inc. (0.10%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Louisiana State Employees Retirement System, Confluence Investment Management LLC, Scout Investments Inc., IMA Wealth Inc. and 6 Meridian. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

CBM stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Fox Run Management L.L.C. and State of Alaska Department of Revenue. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $42.51.

Cambrex has a market capitalization of $1.48 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

The official website for Cambrex is http://www.cambrex.com.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]